NICE gave a 'minded no' to golimumab as a treatment option for rheumatoid arthritis in people who have had therapy with conventional disease-modifying anti-rheumatic drugs (DMARDs) only. This decision was made as there were significant concerns over the analyses provided by the manufacturer, yet the treatment had the potential to be cost-effective. The concerns, highlighted in the ScHARR-TAG report included, the lack of an important health state in the manufacturer's model, the exclusion of trial data that could be used to estimate utilities and no exploration of dose escalation.
For further details contact Rachel Jackson or Sarah Davis.
